CAR-T治疗恶性肿瘤的研究进展及趋势分析

Research progress and trends of chimeric antigen receptor T-cell therapy

嵌合抗原受体修饰的T细胞免疫疗法较传统临床治疗方法具有靶向性强、更持久的疗效,研究进展很快,除公认有效的靶点CD19外,CD20、CD28、CD134等靶点的研究日渐广泛,近期在实体瘤领域也取得了突破性进展。行业领先者诺华的产品CTL019计划于2017年上市,届时市场竞争将非常激烈。但CAR-T疗法还存在亟待解决的安全性问题,如细胞因子释放综合征、脱靶毒性等,部分挑战如费用昂贵、缺乏标准化治疗流程等也阻碍着它的大规模市场化应用。本文将对其临床治疗的优势、研究进展、安全性、市场竞争情况、发展面临的挑战等作整体分析探讨。

The progress of chimeric antigen receptor T-cell therapy is concerned worldwide.Compared with traditional clinical treatments of tumors,the therapy is characterized by targeting and lasting.The cellular immune therapy is developed rapidly.Except for target CD19,targets CD20,CD28 and CD134 are researched more widely.In addition,chimeric antigen receptor T-cell therapy has made a delightful breakthrough in solid tumor field recently.Novartis is the leader of industry.CTL019 is a key product which Novartis intends to market in 2017.However,there are security problems remained to be resolved and several challenges,such as expensive cost and lack of standard treatment procedures,need to conquer.This article would review the superiorities,developments,market competition and challenges of chimeric antigen receptor T-cell therapy.